bluebird bio (BLUE)
(Delayed Data from NSDQ)
$0.51 USD
+0.01 (2.28%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.51 0.00 (0.79%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.51 USD
+0.01 (2.28%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.51 0.00 (0.79%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth A Momentum C VGM
Zacks News
Novo Nordisk (NVO) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Novo Nordisk's (NVO) Diabetes and Obesity Care products are expected to have boosted sales in the second quarter of 2023 amid severe competition and pricing pressure in the United States.
CRISPR (CRSP) to Post Q2 Earnings: What's in the Offing?
by Zacks Equity Research
CRISPR (CRSP) currently does not have any marketed product in its portfolio. The company is expected to provide regulatory updates on exa-cel applications, along with other pipeline updates.
Ligand (LGND) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Ligand's (LGND) second-quarter 2023 performance is likely to have been driven by rising royalty revenues on the back of higher growth in sales of drugs developed using its pelican platform.
NGM Biopharmaceuticals (NGM) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 0% and 42.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of Zoetis' (ZTS) companion animal and livestock products are expected to have driven sales in second-quarter 2023, partially offset by lower sales of swine products.
Adaptimmune (ADAP) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Adaptimmune (ADAP) is expected to provide regulatory and developmental updates on its pipeline programs in its upcoming earnings release, given the absence of marketed products in its portfolio.
Amphastar (AMPH) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Amphastar's (AMPH) revenues in the second quarter of 2023 are expected to have been driven by the sales of its high-margin pharmaceutical products.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
bluebird's (BLUE) Gene Therapy for SCD Gets Priority Review
by Zacks Equity Research
bluebird's (BLUE) gene therapy lovotibeglogene autotemcel gets Priority Review in the United States for sickle cell disease.
Why Is Kodiak Sciences Inc. (KOD) Up 62.9% Since Last Earnings Report?
by Zacks Equity Research
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bluebird (BLUE) Down 26% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
bluebird (BLUE) Posts Q1 Earnings, Focuses on Zynteglo, Skysona
by Zacks Equity Research
bluebird bio (BLUE) delivers earnings of 21 cents per share in the first quarter, due to a one-time gain. Revenues increase year over year.
Company News for May 10, 2023
by Zacks Equity Research
Companies in The News Are: DUK,LITE,ATKR,BLUE
Bluebird Bio (BLUE) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Bluebird (BLUE) delivered earnings and revenue surprises of 138.89% and 89.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stocks' Q1 Earnings on May 9: NVAX, EBS & More
by Kinjel Shah
Let us look at five biotech companies, NVAX, EBS, BLUE, EXEL and NKTR, which are gearing up for their earnings release.
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ovid Therapeutics (OVID) delivered earnings and revenue surprises of -5.56% and 10%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Travere (TVTX) delivered earnings and revenue surprises of -7.63% and 11.90%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Bluebird (BLUE) Up 17.2% Since Last Earnings Report?
by Zacks Equity Research
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights Biogen, Incyte, Morphic Therapeutic and bluebird bio
by Zacks Equity Research
Biogen, Incyte, Morphic Therapeutic and bluebird bio are included in this Analyst Blog.
Biotech Stock Roundup: BIIB's Q1 Results, ARWR Up on Data, INCY & BLUE Offer Updates
by Ekta Bagri
Earnings and pipeline updates from Biogen (BIIB) and Arrowhead (ARWR) are they key highlights of the biotech sector.
The Zacks Analyst Blog Highlights bluebird, Oncternal Therapeutics, Avidity, Ascendis and Vertex Pharmaceuticals
by Zacks Equity Research
bluebird, Oncternal Therapeutics, Avidity, Ascendis and Vertex Pharmaceuticals are included in this Analyst Blog.
Biotech Stock Roundup: BLUE Announces Q4 Results, ONCT, ASND & RNA Fall on Updates
by Zacks Equity Research
Earnings and pipeline updates from bluebird bio (BLUE) and Avidity (RNA) are the key highlights for the biotech sector.
After Plunging -37.53% in 4 Weeks, Here's Why the Trend Might Reverse for Bluebird (BLUE)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Bluebird (BLUE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
bluebird (BLUE) Down on Updates on SCD Therapy, Reports Q4
by Zacks Equity Research
bluebird (BLUE) provides updates on its BLA submission for its experimental gene therapy lovo-cel and reports Q4 results. Shares are down on the same.